Awake Prone Positioning in COVID-19 Suspects With Hypoxemic Respiratory Failure

NCT ID: NCT04853979

Last Updated: 2022-08-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

61 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-05-16

Study Completion Date

2021-07-12

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigator hypothesis is that early implementation of early, awake prone position for patients with COVID-19 pneumonia requiring oxygen therapy will reduce the need for escalation of respiratory support. Escalation of respiratory support is defined as the need for respiratory support with HFNO, NIV or IV.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The world health organization has designated the Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) as an ongoing pandemic and a public health emergency of international concern. The disease is estimated to be severe in 20% of patients and about 5-10% will need critical care with respiratory support. ARDS is thought to be the main cause of respiratory failure in COVID-19 patients. Research is still ongoing to further elucidate the different ARDS subtypes that may exist in COVID-19. It is crucial to find new targets for treatment and support of COVID-19 patients with respiratory failure.

Prone positioning causes a substantial improvement in oxygenation that appear to persist after the patient is returned to a supine position. It has also been shown to have a significant mortality benefit in invasively ventilated ARDS patients. Observational studies have shown improvement in oxygenation with awake prone positioning in non-intubated patients with COVID-19 pneumonia. There is no published RCTs to date. It remains unclear whether prone positioning averts invasive or non-invasive ventilation, accelerates recovery, or reduces mortality. Similarly, there is no data on presumed viral pneumonia. Future studies are needed to identify the optimal indications for, duration of pronation, and assessment of response.

Hypothesis: The investigator hypothesis is that early implementation of early, awake pronation for patients with Covid19 pneumonia requiring oxygen therapy will reduce the need for escalation of respiratory support. Escalation of respiratory support is defined as the need for respiratory support with HFNO, NIV or IV Research participants: Adults 18 years and older with suspected or confirmed COVID-19 presenting to HMC with hypoxemic respiratory failure (PF\<200 or SpO2 less than 94% on FiO2\>=0.4 or =\>5 lit/min O2)

Design: This is a non-blinded randomized controlled trial. Participants will be randomized to one of two study arms:

1. Intervention arm: Any combination of prone or side position (defined as any part of the anterior chest wall being in contact with the bed) for at least 3 hours and up to 16 hours per day during wakefulness. Patients will be asked to prone on three occasions: morning, afternoon and evening. Breaks of 30-120 min are allowed in sitting position or supine each 4 hours. Bed elevation of \>30 degrees will be maintained unless otherwise requested by the patient. No control or intervention is made during sleep periods. Intervention will last for up to 3 days or until the patient achieves oxygen saturations of 94-98% on room air. Oxygen delivery may be via NC, HM, HFNC or NIV.
2. Control arm: Usual care (no Prone unless asleep and assumes this position spontaneously). The patient is able to adopt their preferred natural position. The bed will be elevated \>30 degrees unless requested otherwise by the patient. However prone position may be used as rescue therapy if oxygen requirements are =\>15 lit/min O2 or HFNC/NIV with FiO2 =\>0.6 with O2 saturation less than 90% at the discretion of the treating physician.

Methods and outcomes:

Data will be analyzed for escalation of respiratory support within the first three days of the study. Escalation of respiratory support is defined as follows:

* escalation from NP/HC/NRB to HFNO or NIV or IV
* escalation from HFNO or NIV to IV Several secondary outcomes will be analyzed as well as outlined in outcomes section.

Based on previous studies of prone position in COVID-19 patients, anticipate an improvement in oxygenation and possible prevention of intubation with shorter mechanical ventilation times. Awake proning has been shown to be safe in local practice.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID-19 Patients Hypoxemic Respiratory Failure Prone Position

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Prone position cannot be masked to any member in the trial

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PRONE

Any combination of prone or side position for 3 hours, 3 times a day for 3 days.

Group Type EXPERIMENTAL

PRONE POSITION

Intervention Type OTHER

Any combination of prone or side position for 3 hours, 3 times a day for 3 days

NO PRONE

Usual care

Group Type ACTIVE_COMPARATOR

PRONE POSITION

Intervention Type OTHER

Any combination of prone or side position for 3 hours, 3 times a day for 3 days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PRONE POSITION

Any combination of prone or side position for 3 hours, 3 times a day for 3 days

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* SPO2 less than 94% or Oxygen requirment of more than 5 liters.
* Requiring oxygen therapy in Hospital\< 24 hours

Exclusion Criteria

* Clinical assessment for immediate intervention.
* PF\<50
* SF\<90
* RR\>60bpm
* Hemodynamics instability with need for vasopressors.
* MSOF
* Age\<18
* Pregnancy
* Impaired LOC, agitation or lack of cooperative patient.
* BMI\>40
* Unstable spine or pelvis
* Abdominal wound
* Pnemothorax
* Any injury or illness that may be worsened or result in pain as a result of prone position.
* DNAR
* Any contraindicaton to prone position.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hamad Medical Corporation

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Tim Richard Edmund Harris

Vice chairman Education Emergency Department

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hamad Medical Corporation

Doha, , Qatar

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Qatar

References

Explore related publications, articles, or registry entries linked to this study.

Harris TRE, Bhutta ZA, Qureshi I, Kharma N, Raza T, Hssain AA, Pathare AS, D'Silva A, Khatib MY, Mohamedali MGH, Macineira IMG, Garcia Hernandez VR, Garcia JR, Thomas SH, Pathan SA. A randomised clinical trial of awake prone positioning in COVID-19 suspects with acute hypoxemic respiratory failure. Contemp Clin Trials Commun. 2024 Apr 13;39:101295. doi: 10.1016/j.conctc.2024.101295. eCollection 2024 Jun.

Reference Type DERIVED
PMID: 38689829 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MRC-01-20-1227

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.